Bone Biologics Corporation

NasdaqCM BBLG

Bone Biologics Corporation Price to Earnings Ratio (P/E) on February 06, 2025

Bone Biologics Corporation Price to Earnings Ratio (P/E) is NA on February 06, 2025, a NA change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Bone Biologics Corporation 52-week high Price to Earnings Ratio (P/E) is -0.31 on June 26, 2024, which is NA below the current Price to Earnings Ratio (P/E).
Bone Biologics Corporation 52-week low Price to Earnings Ratio (P/E) is -1.31 on August 02, 2024, which is NA below the current Price to Earnings Ratio (P/E).
Bone Biologics Corporation average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.65.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: BBLG

Bone Biologics Corporation

CEO	Mr. Jeffrey Frelick
IPO Date	Oct. 13, 2021
Location	United States
Headquarters	2 Burlington Woods Drive
Employees	2
Sector	Technology
Industries 3D Printing Biotechnology Clinical Trials Composite Materials Medical Instruments Plastics Robotics

Description

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Key trends

Past 5 years